In this context, promising findings in PC pre-clinical studies have been also obtained by blocking different domains of the multi-enzyme complex fatty acid synthase (FASN) with the two agents, epigallocatechin-3 gallate and orlistat [189,190]. The gene discussed is FASN; the disease is pachyonychia congenita.